Home Search

prostate cancer - search results

If you're not happy with the results, please do another search

LRG1-Targeting MAB Helps Open Tumor Cell Vessels to Treatments

Researchers say the new approach offers the potential to improve outcomes in patients who respond poorly to current standard of care for cancers, including those of the breast, colon, bladder, prostate, and lung.
Diving deep into the waters of genomic heterogeneity allows researchers to focus on the critical association between drug interactions and individual gene variants

Old Antibiotic Targets BRCA-Mutated, PARP Inhibitor-Resistant Tumors

Dana-Farber Cancer Institute scientists have discovered that an antibiotic developed in the 1950s and largely superseded by newer drugs, effectively targets and kills cancer cells that have a common genetic defect in the BRCA1 or BRCA2 genes.
information technology in genome research, bioinformatics concep

10 Startups to Watch

Early-stage companies advance precision medicine by applying AI, clinical genomics, and  other new technologies.
digital dna

Artificial Intelligence Gets Real

Precision medicine startups push forward to train their systems to provide connections and insights from datasets too large and complex for manual analysis.
Roche logo

AVENIO ctDNA Surveillance Kits

The AVENIO ctDNA Surveillance Kit is an NGS liquid biopsy assay that is specially designed to enable researchers to monitor tumor burden in lung and colorectal cancer over time, as well as to assess for minimal residual disease (MRD). This assay contains 471 frequently mutated regions associated with the presence of disease across 197 genes, including those in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1

Roche AVENIO ctDNA Expanded Kits

The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy tumor profiling assay for identifying genomic aberrations derived from solid tumors. This panel contains 77 genes, including those currently in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1 This panel also contains emerging biomarkers relevant to clinical research.
Roche Sequencing and Life Science
9115 Hague Road Indianapolis, IN 46256 855-527-2246 https://sequencing.roche.com/en-us.html
Freenome’s artificial intelligence (AI) genomics platform

Deep Learning Predicts Disease-Associated Mutations

For the first time, a deep-learning approach has been used to predict disease-associated metal-relevant site mutations in metalloproteins, providing a new platform to tackle human diseases.
Glioma - brain tumor

Tumor Microenvironment Key to Personalized Immunotherapy Treatment

The researchers found that combining anti-PD-1 and anti-CTLA-4 immunotherapies in CD73 knockout mice stifled glioblastoma tumor growth and increased survival.

TGen Launches Software to ID Tumor-Causing Mutations from Archival Tumor Samples

LumosVar can detect not only cancerous DNA from an archival sample, but also differentiate the normal DNA that may surround the tumor sample

Biocartis, BMS to Partner on CDx for mCRC Immunotherapy Combination

Partners to develop Biocartis' Idylla MSI test as a companion diagnostic for BMS' Opdivo-Yervoy combo in metastatic colorectal cancer


Inside Precision Medicine